Bartter's syndrome--treatment with potassium, spironolactone and ACE-inhibitor.
The treatment of Bartter's syndrome is fraught with difficulties, and there is no consensus concerning the pathogenetic mechanisms involved. Potassium depletion with hypokaliaemia is a dominant feature of the syndrome. In this case history, a 42-year-old woman suffering from Bartter's syndrome did not improve on several therapeutic trials. An impressive progress was noted, however, after intensive potassium repletion with subsequent potassium/spironolactone/ACE-inhibitor treatment. After 24 months her condition was unchanged with normal and stable Se-potassium concentration.
Clementsen
P
P
Department of Medicine, Naestved Hospital, Denmark.
Høegholm
A
A
Hansen
C L
CL
Damkjaer
M
M
Christensen
P
P
Giese
J
J
D000328:Adult; D001477:Bartter Syndrome / Q000097:blood / Q000188:drug therapy*; D002216:Captopril / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy*; D011188:Potassium / Q000627:therapeutic use*; D012084:Renin-Angiotensin System / Q000187:drug effects; D013148:Spironolactone / Q000627:therapeutic use*
D013148:Spironolactone; D002216:Captopril; D011188:Potassium